HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.6%

Neg 0% Neu 89.6% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.